HYPERTRIGLYCERIDEMIA THERAPEUTICS MARKET ANALYSIS

Hypertriglyceridemia Therapeutics Market, By Type (Primary and Secondary), By Drug Class (Statins, Fibrates, Omega-3 Fatty Acids, HMG-CoA Reductase inhibitors, and Niacin), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jul 2023
Code : CMI4020
Pages :230
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Hypertriglyceridemia Therapeutics Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global hypertriglyceridemia therapeutics market over the forecast period owing to the increase prevalence of CVD such as coronary artery disease and atherosclerosis. For instance, on May 15, 2023, according to the CDC in U.S, coronary heart disease (CHD) is the most common type of heart disease, affecting about 375,476 people in 2021. About 1 in 20 adults age 20 and older have CAD (about 5%) and about 2 in 10 deaths from CAD happen in adults less than 65 years old.

North America: U.S. and Canada

Latin America: Brazil, Argentina, Mexico, and Rest of Latin America

Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe

Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific

Middle East: GCC Countries, Israel, and Rest of Middle East

Africa: South Africa, North Africa, and Central Africa